行情

CLBS

CLBS

Caladrius
NASDAQ

实时行情|Nasdaq Last Sale

2.450
-0.160
-6.13%
已收盘, 16:00 09/19 EDT
开盘
2.680
昨收
2.610
最高
2.690
最低
2.450
成交量
5,524
成交额
--
52周最高
6.83
52周最低
2.160
市值
2,548.41万
市盈率(TTM)
-1.4800
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLBS 新闻

  • 隔夜要闻:美股涨跌不一 微软盘中刷新历史新高
  • 新浪美股.3小时前
  • 中概股周四收平 流利说连跌三天股价创纪录新低
  • 新浪美股.3小时前
  • 市场聚焦沙特供应短缺 美油涨逾1%暂止颓势
  • 汇通网.3小时前
  • 正处于低谷的英伟达 为什么现在值得买入?
  • 新浪科技.4小时前

更多

所属板块

生物技术和医学研究
+0.01%
制药与医学研究
+0.41%

热门股票

名称
价格
涨跌幅

CLBS 简况

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
展开

Webull提供Caladrius Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。